Roche Holding AG (SWX: RO)
Switzerland
· Delayed Price · Currency is CHF 261.20
+0.20 (0.08%)
Dec 20, 2024, 5:30 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,605 employees as of December 31, 2023. The number of employees decreased by 8 or -0.01% compared to the previous year.
Employees
103,605
Change (1Y)
-8
Growth (1Y)
-0.01%
Revenue / Employee
584.73K CHF
Profits / Employee
102.50K CHF
Market Cap
198.60B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | 97,735 | 3,293 | 3.49% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Roche Holding AG | 103,605 |
| Novartis AG | 76,057 |
| Galderma Group AG | 6,545 |
| Galenica AG | 7,902 |
| SKAN Group AG | 1,527 |
| Basilea Pharmaceutica AG | 147 |
| IVF Hartmann Holding AG | 273 |
| COLTENE Holding AG | 1,249 |
Roche Holding AG News
- 2 days ago - Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits - Benzinga
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - The Wall Street Journal
- 2 days ago - Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study - WSJ
- 2 days ago - Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug - Seeking Alpha
- 3 days ago - Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus - GuruFocus
- 3 days ago - Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease - GlobeNewsWire
- 3 days ago - Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease - Business Wire
- 3 days ago - Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche - Investor's Business Daily